『DC EKG』のカバーアート

DC EKG

DC EKG

著者： Stay On Course Studios
無料で聴く

概要

 Join former White House policy expert Joe Grogan as he cuts through the complexities of healthcare legislation and its real-world implications. Each episode of DC EKG aims to demystify the policies shaping our healthcare system, uncovering how these changes impact patients, providers, and payers across the country. New episodes drop every Monday.All Rights Reserved ©2025 政治・政府 政治学 衛生・健康的な生活
エピソード
  • Alzheimer’s in Real Life: Sue Peschin on Early Detection, Biomarkers, CED, and the ASAP Act

    Alzheimer’s in Real Life: Sue Peschin on Early Detection, Biomarkers, CED, and the ASAP Act
    2026/02/17
    In Episode 126 Joe speaks with Sue Peschin, President and CEO of the Alliance for Aging Research, about what Alzheimer’s and dementia look like in the real world and how policy determines who gets help and when. Sue explains the mission and 40–year history of the Alliance for Aging Research and lays out the scope of the Alzheimer’s crisis in plain language: who is affected, how dementia types differ, and why neuropsychiatric symptoms like agitation, psychosis, and depression are so often ignored in policy and practice. They discuss why early detection matters more than ever now that disease-modifying therapies and amyloid inhibitors exist, and why so many cases are still missed in primary care. Sue walks through new blood biomarkers, digital cognitive assessments, and how Medicare coverage, CED restrictions, and the proposed ASAP Act will shape access to testing and treatment. Joe and Sue also dig into Coverage with Evidence Development (CED) in Medicare, whether CMS is overstepping what Congress intended under Section 1801, and how restrictive coverage decisions have limited access to Alzheimer’s drugs to a tiny fraction of eligible patients. Finally, they talk about caregiver burden, stigma around behavioral symptoms, and what families and clinicians can realistically do today. If you care about Alzheimer’s, dementia, early detection, blood biomarkers, Medicare coverage, CED, the ASAP Act, primary care, caregiver burden, vascular dementia, and aging research, this episode connects the science with the politics and the lived experience. In This ConversationJoe and Sue cover: What the Alliance for Aging Research is and why it focuses on “gap” aging and brain health issues How many Americans are living with Alzheimer’s and dementia, including younger-onset cases The difference between Alzheimer’s, vascular dementia, and other dementias, and why neuropsychiatric symptoms matter Why early and accurate detection is critical, even before someone qualifies for a disease-modifying therapy New tools: blood-based biomarkers, digital assessments, PET scans, and when they are used How Medicare coverage, Coverage with Evidence Development (CED), and the ASAP Act affect access to diagnostics and treatments The tension between FDA’s role on safety and effectiveness and CMS’s role on cost control and coverage Timestamps (Audio platforms) 0:00 Intro and Sue’s background / Alliance for Aging Research 5:30 How big is the Alzheimer’s and dementia problem 10:30 Why early detection matters and why diagnoses are still missed 18:30 Neuropsychiatric symptoms, stigma, and caregiver burden 26:30 Blood biomarkers, digital tools, and primary care 33:30 The ASAP Act and Medicare coverage for biomarkers 38:30 Coverage with Evidence Development (CED) and Section 1801 45:00 How to get involved and where to find resources Key Takeaways Alzheimer’s is one of several dementias, and many patients have mixed dementia (Alzheimer’s plus vascular changes). Early detection is vital, not only for disease-modifying therapies, but to rule out other treatable causes and to help families plan. New blood biomarkers and digital assessments could make detection cheaper and easier, but coverage and adoption lag behind the science. Medicare’s CED policy has sharply limited access to Alzheimer’s therapies despite FDA approval and labeled indications. The ASAP Act aims to secure Medicare coverage for Alzheimer’s blood-based biomarkers without waiting on slow guideline processes. About Our GuestSue Peschin is President and CEO of the Alliance for Aging Research, the leading nonprofit focused on advancing science, policy, and education to improve healthy aging and access to care. At the Alliance, Sue has driven national work on Alzheimer’s, dementia, neuropsychiatric symptoms, Medicare policy, CED reform, and aging research, empowering older adults and caregivers to advocate for better care.
    続きを読む 一部表示
    49 分
  • STLDI and ACA Coverage: Costs, Choice, and Tradeoffs

    STLDI and ACA Coverage: Costs, Choice, and Tradeoffs
    2026/01/27
    "Obamacare Exempt" Plans - STLDI and ACA Coverage: Costs, Choice, and Tradeoffs Joe Grogan is joined by Michael Cannon (Cato Institute) to break down short-term, limited-duration insurance (STLDI), also known as “Obamacare-exempt” plans. They explain why STLDI can be far cheaper than ACA exchange coverage, how renewal guarantees work, and why allowing more consumer choice can reduce pressure on exchange risk pools. They also dig into the politics of pre-existing conditions, how ACA rules change insurers' incentives, and why coverage debates often miss the real drivers of cost, access, and quality. The conversation ends with a broader look at public trust, healthcare fear, and how policy choices shape what insurers can and cannot do. Timestamps / Chapters00:01 – Intro00:23 – Michael Cannon joins + what STLDI is02:27 – STLDI explained: “Obamacare-exempt” plans, renewal guarantees, and lower premiums06:00 – ACA history: why STLDI was restricted07:46 – International comparisons + pre-existing conditions incentives and the Colette Briggs story12:10 – Why healthcare stays broken: regulation, lobbying, and “government-designed” systems16:59 – Subsidies and the politics of pre-existing conditions22:22 – Renewal guarantees, employer tax exclusion, and why Medicare entered the picture30:37 – Public trust after Brian Thompson’s murder and Cannon’s letter41:56 – Wrap-up In This Conversation What STLDI is and how it compares to ACA exchange plans Why renewal guarantees matter for long-term protection Risk pools, affordability, and why the “junk insurance” debate persists Pre-existing conditions, politics, and how incentives affect networks and access Why employer-based coverage and Medicare policy shaped today’s system Key Takeaways STLDI is a legal, consumer-driven coverage option that can reduce premiums and expand choice. Renewal guarantees are a major consumer protection that changes the long-term risk story. Pre-existing conditions policy is often debated emotionally, but incentives determine outcomes. About Our GuestMichael Cannon is the Director of Health Policy Studies at the Cato Institute and a leading voice on the ACA, health insurance regulation, and market-based health reforms.
    続きを読む 一部表示
    44 分
  • Ryan Long on the ACA Subsidy Fight, Phantom Enrollees, and Reforming 340B

    Ryan Long on the ACA Subsidy Fight, Phantom Enrollees, and Reforming 340B
    2026/01/27
    Podcast TitleDC EKG with Joe Grogan: A Healthcare Policy Podcast Episode124 Episode TitleRyan Long on the ACA Subsidy Fight, Phantom Enrollees, and Reforming 340B Episode DescriptionJoe Grogan is joined by Ryan Long of Paragon Health Institute and the University of Southern California to break down two fights shaping health policy right now: a California wealth tax pitch framed as a health care fix, and the battle over extending enhanced Affordable Care Act subsidies. They unpack how enhanced subsidies changed who qualifies, why zero-premium plans opened the door to broker-driven enrollment and fraud, and why the medical loss ratio creates perverse incentives that can push premiums higher. They also explain how silver loading and cost-sharing reduction policy distort the exchange market, and what reforms could lower costs without writing a blank check. The episode closes with Ryan's latest work on the 340B program, including why drug arbitrage rewards hospitals with a stronger commercial mix and can fuel consolidation, and why direct, targeted assistance could better support hospitals that truly serve low-income and rural patients. Chapters and Timestamps00:01 Intro00:23 Welcome, and what is on the agenda01:25 California wealth tax and structural deficits11:20 Enhanced ACA subsidies and the shutdown fight16:54 Income caps, zero premium plans, and phantom enrollees21:50 Fraud, Medicaid exposure, and public trust30:39 Medical loss ratio incentives and ACA market fixes38:41 340B: how arbitrage works and why it drives consolidation44:51 What reform could look like47:20 Closing SEO KeywordsAffordable Care Act, ACA subsidies, enhanced subsidies, premium tax credits, exchange plans, zero premium plans, phantom enrollees, medical loss ratio, cost sharing reduction, silver loading, Medicaid fraud, Minnesota fraud, California wealth tax, 340B program, drug arbitrage, hospital consolidation, site neutral payments, commercial mix, Medicare Trust Fund About Our GuestRyan Long is a health policy expert with experience on Capitol Hill, including years in the Speaker's office and on the House Energy and Commerce Committee. He is affiliated with Paragon Health Institute and the University of Southern California. CreditsSponsor: Survivors for SolutionsExecutive Producer: John “CZ” Czwartacki, DC EKG PodcastProducer: Julie Riga, Stay on Course Studios, https://www.stayoncourse.studio
    続きを読む 一部表示
    49 分
まだレビューはありません